

	<p>Empagliflozin EU Risk Management Plan</p> <p>Version: 0.3 Date: 18 March 2026</p>
---	---

Part VI: Summary of the risk management plan

Summary of risk management plan for Empagliflozin Reddy 10 mg filmdragerade tabletter, Empagliflozin Reddy 25 mg filmdragerade tabletter (Empagliflozin Reddy)

This is a summary of the risk management plan (RMP) for Empagliflozin Reddy 10 mg filmdragerade tabletter, Empagliflozin Reddy 25 mg filmdragerade tabletter (Hereinafter referred to as “Empagliflozin Reddy”). The RMP details important risks of Empagliflozin Reddy, how these risks can be minimised, and how more information will be obtained about Empagliflozin Reddy's risks and uncertainties (missing information).

Empagliflozin Reddy's summary of product characteristics (SmPC) and its Package Leaflet (PL) give essential information to healthcare professionals and patients on how Empagliflozin Reddy should be used.

Important new concerns or changes to the current ones will be included in updates of Empagliflozin Reddy's RMP.

I. The medicine and what it is used for

Empagliflozin Reddy is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise

- as monotherapy when metformin is considered inappropriate due to intolerance
- in addition to other medicinal products for the treatment of diabetes.

Empagliflozin Reddy is indicated for the treatment of symptomatic chronic heart failure and chronic kidney disease (see SmPC for full indication). It contains empagliflozin as the active substance and it is given by oral administration.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Empagliflozin Reddy, together with measures to minimise such risks and the proposed studies for learning more about Empagliflozin Reddy's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the PL and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size - the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status - the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

	Empagliflozin EU Risk Management Plan
	Version: 0.3 Date: 18 March 2026

II.A List of important risks and missing information

Important risks of Empagliflozin Reddy are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Empagliflozin Reddy. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

List of important risks and missing information	
Important identified risks	<ul style="list-style-type: none"> • None
Important potential risks	<ul style="list-style-type: none"> • None
Missing information	<ul style="list-style-type: none"> • None

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Empagliflozin Reddy.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Empagliflozin Reddy.